机译:Codrituzumab对肝细胞癌患者整体存活的效果的延时建模
Translational Clinical Research Science &
Strategy Dept.Chugai Pharmaceutical Co. Ltd.Tokyo Japan;
Translational and Clinical Research Center Hoffmann-La Roche Inc.New York City USA;
Clinical PharmacologyF. Hoffmann‐La Roche Ltd.Basel Switzerland;
Translational Clinical Research Science &
Strategy Dept.Chugai Pharmaceutical Co. Ltd.Tokyo Japan;
Translational and Clinical Research Center Hoffmann-La Roche Inc.New York City USA;
Translational Clinical Research Science &
Strategy Dept.Chugai Pharmaceutical Co. Ltd.Tokyo Japan;
Translational Clinical Research Science &
Strategy Dept.Chugai Pharmaceutical Co. Ltd.Tokyo Japan;
Project Planning &
Coordination Dept.Chugai Pharmaceutical Co. Ltd.Tokyo Japan;
Memorial Sloan Kettering Cancer CenterNew York NY USA;
Translational and Clinical Research Center Hoffmann-La Roche Inc.New York City USA;
GC33/codrituzumab; GPC3; hepatocellular carcinoma; overall survival; pharmacokinetics; time‐to‐event model;
机译:Codrituzumab对肝细胞癌患者整体存活的效果的延时建模
机译:肝细胞癌患者的I-124屈妥珠单抗成像和生物分布
机译:Codrituzumab在先前治疗的晚期肝细胞癌患者中的随机II期安慰剂对照研究
机译:使用过采样和机器学习技术的肝细胞癌患者的存活预测
机译:肝细胞癌热消融引起热应激的细胞死亡和存活机制
机译:依托妥珠单抗对肝细胞癌患者总生存时间的事件建模
机译:与时间相关的COX模型在预测肝细胞癌经经皮化学成形术治疗的患者中的生存率方面具有优势